The introduction of antibody-conjugate drugs has reshaped the HER2 landscape, as seen in studies like DESTINY Breast04, where trastuzumab deruxtecan demonstrated efficacy in HER2-low BC (13). Here, ERBB2 is linked to breast cancer.